In vitro production of lectibody and bispecific antibodies targeting surface glycoproteins of SARS-CoV-2 by the novel off-the-shelf approach

Description of the granted funding

Antibodies play a critical defensive role in virus infections in humans. Vaccine-induced immunity could protect humans from COVID-19 by producing neutralizing antibodies. However, viruses have multiple strategies to evade antiviral immune responses of the host, e.g., by hijacking the host glycosylations systems to coat virus surface with glycans. Whereas neutralizing antibodies bind viral surface proteins, lectins from natural sources are known to have high antiviral activities by binding to the surface glycans on enveloped viruses, including SARS-COV-2. The novel off-the-shelf approach by the protein ligation technology opens a new avenue to produce various lectin-Fc fusion in vitro, termed lectibody. Bispecific lectin-antibodies, which can engage NK cells or T-cells, could inhibit viral infections as well as remove infected cells. The off-the-shelf approach could produce various drug candidates in vitro rapidly and also particularly useful for rapidly emerging infectious diseases.
Show more

Starting year

2020

End year

2022

Granted funding

Adrian Goldman Orcid -palvelun logo
362 307 €

Funder

Research Council of Finland

Funding instrument

Targeted Academy projects

Other information

Funding decision number

336450

Fields of science

Biochemistry, cell and molecular biology

Research fields

Biokemia, biofysiikka

Themes

Lisätalousarvio III 2020

Identified topics

covid, pandemic, vaccines